Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapeutics > Ex. 6 - GI Protection (61-62) > Flashcards

Ex. 6 - GI Protection (61-62) Flashcards

1
Q

Drugs affecting gastric secretion

A

Antacids
H2 histamine receptor antagonists
PPIs
Protectants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Drugs that increase GI motility

A

Laxatives
Prokinetic drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Reduce GI motility

A

Anti-diarrheals
Anti-emetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Acid-peptic disease drugs used in tx of

A

Non-ulcer dyspepsia (indigestion)
Gastric and duodenal ulcers

GERD - Barrett’s Esophagus

Hypersecretory states such as Zollinger- Ellison syndrome
^Rare
Tumors that produce gastrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Physiologic control of GI secretions

A

Parietal cell
in epithelium of stomach
Secretes acid into the lumen of stomach
**stimulated by activation of M3 receptors, AcH, histamine (H2 receptors) and gastrin

Conversion: Proton ATPase
-Moves protons into the stomach
-It does so by moving potassium into the parietal cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Why do we have sensitivity to receptors in the parietal cell?

A

These are physiological modulators on the acid secretion of gastrin

Gastrin released in response to food intake
-Directly stimulates parietal cells
-Stimulates ECL cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ECL Cells

A

Contain granules of histamine
Gastrin stimulation stimulates the release of histamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Feedback loop

A

Lumen of the stomach = highly acidic: inhibitory signal for further acid secretion
-Achieved through activation of D cells which release Somatostatin
Inhibits release of gastrin
-Yellow in graphic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Make up the most of the endothelium of the stomach

A

Surface epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Surface epithelial cells

A

Secrete mucus and bicarbonate within lumen of the stomach
-Protects underlying tissue from acid erosion

Mucus is a physical barrier - within mucus bicarbonate secreted by surface epithelial cells and creates a buffer within mucus to help neutralize and protect stomach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prostaglandins (PGE2 and PGI2)

A

Persistent innovation of prostaglandin synthesis protects the stomach
-Protects through mucosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Systemically absorbed Antacids

A

NaHCO3

Neutralizing capacity: High
Adverse: Systemic alkalosis, fluid retention; excess gas
(CO2)

CaCO2

Neutralizing capacity: Moderate
Adverse: Hypercalcemia, nephrolithhiasis, milk-alkali syndrome (CO2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Minimally absorbed antacids

A

Al(OH)3

Neutralizing capacity:
High
Adverse:
Constipation, hypophosphatemia if absorbed; encephalopathy

Mg(OH)2
Neutralizing capacity:
High
Adverse:
Diarrhea
If absorbed: CNS toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Commercial Antacids

A

AlternaGEL - AL(OH)3
Tums - CaCO3
Maalox, Mylanta - Al(OH3) and Mg(OH)2
Rolaids - CaCO3 & Mg(OH)2
Alka-Seltzer - ASA and NaHCO3

Gaviscon (sodium alginate + antacids) - Viscous, weak base
-Prevents reflux
Effective in GERD

Chewable tabs vs liquid suspension
-Liquid more popular but more expensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

H2 Histamine Receptor Antagonists - Cimetidine (Tagamet)

A

Competitive antagonist of H2 Histamine Receptor
-Reduce gastric acid secretion in response to histamine, gastrin, AcH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

H2 Histamine Receptor Antagonists - second gen

A

Ranitidine
-No longer available
Nizatidine
Famotidine

Competitive antagonists of H2 histamine receptor
Reduce gastric acid secretion in response to histamine, AcH, gastrin
Longer half-life (Hs vs. BID dosing)
Fewer effects on CYP450 system
Greater potency
Absorbed quickly to reduce parietal cell function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

PPIs

A

Main target for acid secretion in the stomach
-Red section on graphic
-inhibiting ultimate step of pathway
-Can suppress acid secretion of M2/3, Gastrin, and H2 receptors by blocking P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

PPI types - Bezimidazoles

A

Esomeprazole (Nexium), omeprazole (prilosec)
-Same molecule, eso is purified S enantiomer - slightly more potent

Lansoprazole (Prevacid)

Raberprazole (Aciphex)

Panntoprazole (Protonix)

Dexlansoprazole (Dexilant)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PPI MOA

A

Have to be activated in the acidic environment of parietal cell
-essentially irreversible mechanism
-Why the drugs have such a long half-life
-You would have to replace the proton pumps to fix

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

*8Summary of PPI actions**

A

Must be absorbed in the SI (acidic), circulate and then be taken up by the parietal cells. This leads to slow onset

Prodrugs: Activated by acidic pH (IN the parietal cell)

Irreversible inhibitor of H+/K+-ATPase (Cys813)

Short plasma half-life (1hour) but long duration of action due to covalent inhibition (24hrs) and slow turnover of proton pumps

Hypergastrinemia occurs, and MAY result in rebound hypersecretion of gastric acid upon drug withdrawal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Main difference between PPIs and H2 antagonists

A

H2 receptor antagonists = not as efficient at suppressing nocturnal acid as PPI

Bypassing H2 receptor blocker are good at suppressing response toward food, but not so much in general

22
Q

Acid rebound

A

Increased gastric acid secretion upon withdrawal of acid-suppressing meds

Reduced gastric acid removes somatostatin’s inhibition of gastrin secretion - Hypergastrinemia

Tolerance to H2 antagonists can occur

23
Q

Risk associated with suppressing acid secretion

A

Potentially increase risk of infections:
-Primary role of acid in stomach is to kill of bacteria
-Suppress too much acid - nothing to kill bacteria

Vitamin B12 deficiency:
-No acidity = Vitamin B12 does not efficiently unbind from enzymes and then it is poorly absorbed

Decreased Ca2+ absorption/increased bone fractures:
-Ca salts absorption need acidic environment to be absorbed properly = decrease in plasma calcium conc
Hypergastrinemia
-Simulate PTH
-Simulate bone resorption
-Decreases bone strength

24
Q

PPI - Vonoprazan

A

Potassium-competitive acid blocker (P-CAB)
Approved 2023
Advantages:
-Faster acid suppression
-NOT prodrug
-Not influenced by meals
-Very stable in low pH

“ATP-driven H+ export into the gastric lumen an uptake of K+ into the cytoplasm thought to vary from 2H/2K to 1H/1K per ATP as the luminal pH decreases

25
Q

Mucosal Protective Agents - Sucralfate (Carafate)

A

Aluminum hydroxide complex of sucrose
-Polymerizes and forms protective barrier at ulcer site
-Acidic pH activates complex
-Poorly absorbed
-Used in conjunction w/other drugs
-Given for a long period of time - lumen toxicity

26
Q

Mucosal Protective Agents - Misoprostol (Cytotec)

A

Semi-synthetic prostaglandin E1 derivative
-Reduced acid secretion (parietal cell)
-Cytoprotectant effects - enhanced mucus and bicarbonate secretion
-Used in combination with chronic NSAIDs
AE: Diarrhea, Abortifacient

27
Q

H. Pylori and Peptic Ulcers

A

Many peptic ulcers are associated w/ infection of the gastric mucosa by the gram-negative bacilli, Helicobacter Pylori

Noble Prize in 2005 - Barry Marshall and Robin Warren

H. Pylori infection detected by:
13/14 -labelled urea
H2N-CO-NH2
(detects urease activity)
PCR stool sample

28
Q

H. pylori eradication: Bismuth Subsalicyclate (Pepto-Bismol)

A

Converted to bismuth salts and salicylic acid in the GI tract
-Antibacterial, Antiviral, and antisecretory activity
Uses: Nausea, heartburn, indigestion, upset stomach, diarrhea
-Part of multi-drug therapy for H. Pylori eradication

29
Q

H Pylori Eradication - Other drugs

A

Therapy consists of tx with various combinations of:
-Bismuth Salt (Pepto)
-Antibiotic - Metronidazole, Tetracycline, Amoxicillin
-H2 blocker or PPI

30
Q

Laxatives

A

Prokinetic drugs that can stimulate GI motility
Most common: Bulk laxatives
NOT absorbed - form a hydrophilic acid in the GI tract - causes fluid to be retained in the tract, causes contractions

31
Q

Bulk and osmotic laxatives

A

Fiber laxatives; Psylium (Metamucil), Methylcellulose, (Citrucel), calcium polycarbophil (fiberCon)
Peg 3350 (MiraLax) aka Macrogol (Movicol)
Isosmotic electrolyte solutions w/PEG 3350 (GoLytely) produce similar effects
(PEG 3350)

Lactulose (duphalac) a non-absorbable sugar has an osmotyic affect. Also, fermented by bacteria in the gut producing acetate which stimulates peristalsis
-Sugar free gummies have a non-absorbable sugar alcohol called malitol. This also forms hydrophilic mass in the presence of water

-Increase water in the intestinal lumen by osmotic force, leading to distention and an increase in peristalsis

32
Q

Laxatives - Stool Softeners

A

Docusate Sodium (colace), mineral oil, glycerin
-Surfactants and lubricants
-Incorporate into stool to make passage easier and decrease water absorption
-Lubricate lower bowel to reduce fecal impaction
-Can decrease absorption of fat-soluble vitamins

33
Q

Secretory or Stimulant Laxatives

A

Poorly understood mechanism
Castor oil: hydrolyzed in the upper small intestine to ricinoleic acid

Diphenylmethane Derivatives: Bisacodyl (Dulcolax)

Anthraquinones: Cascara, senna, and aloes

Irritation of the mucosa affects fluid secretion/absorption balance and induces peristalsis

34
Q

Common GI Hypomotility Disorders

A

Gastroparesis
-Neuropathy during diabetes or Parkinson’s disease

Ileus
-Small bowels don’t recover after surgery

Opioid induced constipation
-Peripheral activation of opioid receptors slows down the G.I system

35
Q

Prokinetic Drugs

A

Prucalopride
Erthyromycin
Bethanechol
Metoclopramide - D2 receptor
Neostigmine

36
Q

Prokinetic - Metoclopramide (Reglan)

A

D2 Dopamine receptor antagonist
-Blockade of D2 receptors in the myenteric plexus leads to increase acetylcholine release
-D2 receptor blockade also produces anti-emetic effects
-Clinical Uses: Promotes gastric emptying to facilitate small bowel intubation, post op and diabetic gastroparesis, gastro-esophageal reflux disease (GERD)
-Can lead to acute dystonic reactions

37
Q

Opioid receptor antagonists

A

Centrally acting: anit-addictive agents
-Naloxone (Narcan)
-Naltrexone
-Nalmefene

Peripherally acting (cannot cross BBB)
-Naloxegol (Movantik)
-Albimopan (Entereg)
-Naldemedine (SYMPROIC)

38
Q

Prokinetic Drugs - Prucalopride (Motegrity)

A

5HT4 receptor agonist
5HT4 serotonin receptor, GPCR, GaS coupled, activation leads to increased cAMP, PKA activation and release of ACH
-Indicated for the tx of chronic idiopathic constipation (CIC) in adults

39
Q

Tegaserod (Zelnorm)

A

5HT4 agonist
5HT4: Serotonin receptor, GPCR, GaS coupled activation leads to increased cAMP, PKA activation and release of ACH
Indicated for the tx of IBS with constipation in women under 65

40
Q

Increased _ in the gut will lead to increased Na+, and therefore Increased H2O

A

Cl-
Downregulation of cytokines = Decreased Pain

41
Q

Chloride Channel Activators

A

Increase Cl- rich fluid secretion into intestine
For treatment of IBS + constipation
Not absorbed systemically

Lubprostone (Amatiza)
-Stimulation of type 2 cl channel (ClC-2) activator in small intestine

**Linaclotide (Linzenss) - Plecanatide (Trulance)
-A peptide activator of guanylate cyclase C (GC-C)

42
Q

Prokinetic drugs - Tenapanor

A

Sodium/hydrogen exchanger inhibition
-Sodium/Hydrogen exchanger (NHE3) is expressed on the luminal side of small bowel and colonic epithelial cells
-NHE3 functions to absorb sodium from the luminal contents
-Increased Na+ in the gut leads to increased water in the gut accelerating transit of intestinal contents
-This affect can also be achieved through direct treatment with a sodium phosphate (Fleet) enema

43
Q

Anti-Diarrheals - Opiates

A

Slow peristalsis to increase water and electrolyte absorption
Opiates = inhibition of presynaptic cholinergic nerves
Diphenoxylate (Diphenoxylate + atropine = Lomotil)
-Active in the CNS
Loperamide (Imodium)
-Poorly traverse the BBB
-Act locally to delay gastric emptying

44
Q

Reduce Gi motility - 5HT3 receptor antagonist

A

Alosetron (Lotronex
Blocks visceral afferent pain sensation and decreases colon motility
-GI Se - constipation, ischemic colits

Don’t confuse IBS with IBD

45
Q

GI drugs - the enteric nervous system

A

Intrinsic primary afferent neuron
-Submucosal PAN

Extrinsic primary afferent - nausea, vomiting, pain
-Dorsal root or cranial nerve afferent

Enteric Nervous System Neuron increased peristalsis

46
Q

Emetic response

A

Acute irritation of gastrointestinal mucosa
-Mechanoreceptors, Chemoreceptors
5HT3- receptors

Chemoreceptor trigger zone (area postrema)
-D2 receptor
-NK receptor?
-5-HT3 receptor

Vomiting center (nucleus of tractus solitarius
-H1 receptor
-M1 receptor
-NK receptor?
(5-HT3 receptor)

47
Q

Anti-Emetics: 5-HT3 Receptor antagonists

A

Ondansetron (Zofran), Grainsetron (Kytril), Dolasetron, palonosetron
-Block activity of afferent nerves from stomach and small intestine which activate the trigger center in the CNS
-Clinical use: Nausea and vomiting associated w/chemotherapy
SE: Constipation

48
Q

Anti-Emetics: NK1 antagonists

A

Aprepitant, Netupitant, Rolapitant - receptors in chemoreceptor trigger zone

-Combined with 5HT3 receptor antagonits; Akynzeo is combination of Netupitant and palonsetron

49
Q

Anti-Emetics: Antihistmaines/Anitcholinergics

A

Dimenhydrinate (Dramamine) = Diphenhydramine - H1 antagonist + the stimulant 8-chlorotheophylline
-Meclizine (Antivert)-H1 antagonist
-Promethazine -H1 antagonist
-Scopolamine - Muscarinic receptor antagonist

Used to prevent MOTION SICKNESS

50
Q

Anti-Emetics: D2 dopamine receptor antagonists

A

-Anti-emetic and sedative properties
-Also has antimuscarinic and anthistamine effects
-Can cause acute disotonic reactions

-metoclopramide = Reglan
-Prochlorperazine = Compazine
-Droperidol = Inapsine

51
Q

Activation of opioid receptors in the myenteric plexus:

A
  1. Decrease smooth muscle contraction
  2. Increases rectal sphincter tone
  3. Decreases colonic mucosa secretion

Therapeutics (49 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions